June 9, 2020 / 5:44 AM / 2 months ago

BRIEF-Erytech Updates On Phase 2 Eryaspase Trial In Acute Lymphoblastic Leukemia

June 9 (Reuters) - ERYTECH PHARMA SA:

* PROVIDES UPDATE ON PHASE 2 INVESTIGATOR SPONSORED TRIAL OF ERYASPASE IN SECOND-LINE ACUTE LYMPHOBLASTIC LEUKEMIA

* ENCOURAGING PRELIMINARY RESULTS BASED ON INTERIM DATA

* PRELIMINARY FINDINGS OF STUDY SUGGEST THAT ERYASPASE ACHIEVED TARGET LEVEL AND DURATION OF ASPARAGINASE ACTIVITY IN THESE PATIENTS

* UNMET MEDICAL NEED CONFIRMED BY FDA

* PATIENT ENROLLMENT COMPLETED; 50 PATIENTS IN TRIAL Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below